# EDGAR Filing Document

**Accession Number:** 0001706431
**File Stem:** 0001628280-26-010757
**Filing Date:** 2026-2
**Character Count:** 22595
**Document Hash:** d462487f8dfc504300e1e92f60b528f3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-26-010757.hdr.sgml**: 20260223

**ACCESSION NUMBER**: 0001628280-26-010757

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 16

**REFERENCES 429**: 333-234212

**REFERENCES 429**: 333-237410

**REFERENCES 429**: 333-253547

**REFERENCES 429**: 333-263088

**REFERENCES 429**: 333-270108

**REFERENCES 429**: 333-277358

**REFERENCES 429**: 333-285294

**FILED AS OF DATE**: 20260223

**DATE AS OF CHANGE**: 20260223

**EFFECTIVENESS DATE**: 20260223

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Vir Biotechnology, Inc.
- **CENTRAL INDEX KEY:** 0001706431
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 812730369
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-293665
- **FILM NUMBER:** 26666634

**BUSINESS ADDRESS:**
- **STREET 1:** 1800 OWENS STREET
- **STREET 2:** SUITE 900
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94158
- **BUSINESS PHONE:** 415-906-4324

**MAIL ADDRESS:**
- **STREET 1:** 1800 OWENS STREET
- **STREET 2:** SUITE 900
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94158

&nbsp;&nbsp;&nbsp;&nbsp;

**As filed with the Securities and Exchange Commission on February 23, 2026**

**Registration No. 333-** 

<u><br></u>

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**&nbsp;&nbsp;&nbsp;&nbsp;Washington, D.C. 20549 &nbsp;&nbsp;&nbsp;&nbsp;**

<u><br></u>

**Form S-8** 

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

<u><br></u>

**Vir Biotechnology, Inc.** 

**(Exact name of registrant as specified in its charter)** 

<u><br></u>

---

| | |
|:---|:---|
| **Delaware** | **81-2730369** |
| **(State or other jurisdiction of**<br>**incorporation or organization)** | **(IRS employer**<br>**identification number)** |
| **1800 Owens Street, Suite 900**<br>**San Francisco, California** | **94158** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

**2019 Equity Incentive Plan** 

**2019 Employee Stock Purchase Plan** 

**(Full titles of the plans)** 

**Marianne De Backer, M.Sc., Ph.D., MBA** 

**Chief Executive Officer** 

**Vir Biotechnology, Inc.** 

**1800 Owens Street, Suite 900** 

**San Francisco, California 94158** 

**(Name and address of agent for service)** 

**(415) 906-4324** 

**(Telephone number, including area code, of agent for service)** 

***Copies to:***

**Alexa Belonick**

**Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP** 

**550 Allerton Street** 

**Redwood City, California 94063** 

**(650) 321-2400** 

<u><br></u>

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☒ | Accelerated filer | ☐ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
| Emerging growth company | ☐ | | |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

<u><br></u>

------

**STATEMENT OF INCORPORATION BY REFERENCE** 

Vir Biotechnology, Inc. (the "Registrant") is filing this Registration Statement on Form S-8 for the purpose of registering an additional 6,973,747 shares of common stock, par value $0.0001 per share, of the Registrant (the "Common Stock") under the Vir Biotechnology, Inc. 2019 Equity Incentive Plan (the "Incentive Plan") and an additional 1,394,749 shares of Common Stock under the Vir Biotechnology, Inc. 2019 Employee Stock Purchase Plan (the "ESPP"), pursuant to the provisions of each plan which provide for annual automatic increases in the number of shares of Common Stock reserved for issuance under each plan. In each case, the additional shares are of the same class as other securities for which a Registration Statement on Form S-8 relating to the Incentive Plan and the ESPP has previously been filed and is effective. Accordingly, this Registration Statement incorporates by reference the contents of:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the Registration Statement on <u>[Form S-8](http://www.sec.gov/Archives/edgar/data/0001706431/000119312519267739/d809856ds8.htm)</u>, File No. 333-234212, filed with the Securities and Exchange Commission (the "Commission") on October 15, 2019 by the Registrant relating to the Incentive Plan and the ESPP,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the Registration Statement on <u>[Form S-8](http://www.sec.gov/Archives/edgar/data/0001706431/000119312520087036/d898891ds8.htm)</u>, File No. 333-237410, filed with the Commission on March 26, 2020 by the Registrant relating to the Incentive Plan and the ESPP,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the Registration Statement on <u>[Form S-8](http://www.sec.gov/Archives/edgar/data/0001706431/000119312521057294/d109143ds8.htm)</u>, File No. 333-253547, filed with the Commission on February 25, 2021 by the Registrant relating to the Incentive Plan and the ESPP,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the Registration Statement on <u>[Form S-8](https://www.sec.gov/Archives/edgar/data/1706431/000119312522058033/d152492ds8.htm)</u>, File No. 333-263088, filed with the Commission on February 28, 2022 by the Registrant relating to the Incentive Plan and the ESPP,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the Registration Statement on <u>[Form S-8](https://www.sec.gov/Archives/edgar/data/1706431/000095017023005145/form_s-8_2023_evergreen.htm)</u>, File No. 333-270108, filed with the Commission on February 28, 2023 by the Registrant relating to the Incentive Plan and the ESPP,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the Registration Statement on <u>[Form S-8](https://www.sec.gov/Archives/edgar/data/1706431/000119312524046227/d730348ds8.htm)</u>, File No. 333-277358, filed with the Commission on February 26, 2024 by the Registrant relating to the Incentive Plan and the ESPP, and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the Registration Statement on <u>[Form S-8](https://www.sec.gov/Archives/edgar/data/1706431/000162828025008248/a20250226forms-8.htm)</u>, File No. 333-285294, filed with the Commission on February 27, 2025 by the Registrant relating to the Incentive Plan and the ESPP,

except in each case with respect to "Item 8. Exhibits" thereof.

------

**PART II** 

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT** 

**Item 8. Exhibits.** 

The exhibits to this Registration Statement are listed below:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | | **Incorporation by Reference** | **Incorporation by Reference** | **Incorporation by Reference** | **Incorporation by Reference** | **Incorporation by Reference** |
| | | **Incorporation by Reference** | **Incorporation by Reference** | **Incorporation by Reference** | **Incorporation by Reference** | **Incorporation by Reference** |
|<br>**Exhibit**<br>**Number** |<br>**Exhibit Description** | **Form** | **File Number** | **Exhibit Reference** | **Filing Date** | **Filed Herewith** |
| 4.1 | <u>[Amended and Restated Certificate of Incorporation](http://www.sec.gov/Archives/edgar/data/0001706431/000119312519268465/d820601dex31.htm)</u> | 8-K | 001-39083 | 3.1 | 10/16/2019 |  |
| 4.2 | <u>[Amended and Restated Bylaws](https://www.sec.gov/Archives/edgar/data/1706431/000119312523064485/d478454dex31.htm)</u> | 8-K | 001-39083 | 3.1 | 03/08/2023 |  |
| 4.3 | <u>[Specimen common stock certificate](http://www.sec.gov/Archives/edgar/data/1706431/000119312519257981/d755217dex41.htm)</u> | S-1/A | 333-233604 | 4.1 | 09/30/2019 |  |
| 4.4 | <u>[Vir Biotechnology, Inc. 2019 Equity Incentive Plan](http://www.sec.gov/Archives/edgar/data/0001706431/000119312519267739/d809856dex48.htm)</u> | S-8 | 333-234212 | 4.8 | 10/15/2019 |  |
| 4.5 | <u>[Forms of Option Grant Notice and Option Agreement under the Vir Biotechnology, Inc. 2019 Equity Incentive Plan](http://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex103.htm)</u> | S-1 | 333-233604 | 10.3 | 09/03/2019 |  |
| 4.6 | <u>[Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the Vir Biotechnology, Inc. 2019 Equity Incentive Plan](http://www.sec.gov/Archives/edgar/data/0001706431/000156459021008915/vir-ex105_2690.htm)</u> | 10-K | 001-39083 | 10.5 | 02/25/2021 |  |
| 4.7 | <u>[Vir Biotechnology, Inc. 2019 Employee Stock Purchase Plan](http://www.sec.gov/Archives/edgar/data/0001706431/000119312519267739/d809856dex411.htm)</u> | S-8 | 333-234212 | 4.11 | 10/15/2019 |  |
| 5.1\* | <u>[Opinion of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, counsel to the Registrant](a20260223forms-8ex51gunder.htm)</u>.  |  |  |  |  | X |
| 23.1\* | <u>[Consent of Independent Registered Public Accounting Firm.](a20260223forms-8ex231eycon.htm)</u>  |  |  |  |  | X |
| 23.2\* | <u>[Consent of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, counsel to the Registrant (included in Exhibit 5.1).](a20260223forms-8ex51gunder.htm)</u> |  |  |  |  | X |
| 24.1\* | <u>[Power of Attorney (included on the signature page to this Registration Statement).](#i97e572afc35c41c2847d74039012ff0b_179)</u> |  |  |  |  | X |
| 107\* | <u>[Calculation of Filing Fee Tables.](exfilingfees.htm)</u> |  |  |  |  | X |

---

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Francisco, State of California, on February 23, 2026.

---

| | |
|:---|:---|
| **Vir Biotechnology, Inc.** | **Vir Biotechnology, Inc.** |
| By: | /s/ Marianne De Backer |
|  | Marianne De Backer, M.Sc., Ph.D., MBA |
|  | Chief Executive Officer and Director |

---

------

**POWER OF ATTORNEY** 

**KNOW ALL PERSONS BY THESE PRESENTS,** that each person whose signature appears below constitutes and appoints Marianne De Backer, M.Sc., Ph.D., MBA, Jason O'Byrne. MBA, and Vanina de Verneuil, J.D., and each or any one of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Marianne De Backer | Chief Executive Officer and Director<br>(*Principal Executive Officer*) | February 23, 2026 |
| Marianne De Backer, M.Sc., Ph.D., MBA | Chief Executive Officer and Director<br>(*Principal Executive Officer*) |  |
| /s/ Jason O'Byrne | Executive Vice President and Chief Financial Officer<br>(*Principal Financial Officer*) | February 23, 2026 |
| Jason O'Byrne, MBA | Executive Vice President and Chief Financial Officer<br>(*Principal Financial Officer*) |  |
| /s/ Brent Sabatini | Senior Vice President and Chief Accounting Officer | February 23, 2026 |
| Brent Sabatini, CPA, MBA | (*Principal Accounting Officer*) |  |
| /s/ Vicki Sato | Chairman of the Board of Directors | February 23, 2026 |
| Vicki Sato, Ph.D. | Chairman of the Board of Directors |  |
| /s/ Norbert Bischofberger | Director | February 23, 2026 |
| Norbert Bischofberger, Ph.D. |  |  |
| /s/ Ramy Farid | Director | February 23, 2026 |
| Ramy Farid, Ph.D. |  |  |
| /s/ Jeffrey S. Hatfield | Director | February 23, 2026 |
| Jeffrey S. Hatfield | Director |  |
| /s/ Robert More | Director | February 23, 2026 |
| Robert More | Director |  |
| /s/ Janet Napolitano | Director | February 23, 2026 |
| Janet Napolitano | Director |  |
| /s/ Saira Ramasastry | Director | February 23, 2026 |
| Saira Ramasastry |  |  |
| /s/ Elliott Sigal | Director | February 23, 2026 |
| Elliott Sigal, M.D., Ph.D. |  |  |

---

## Exhibit 5.1

Exhibit 5.1

![a1a.jpg](a1a.jpg)![a11a.jpg](a11a.jpg)

February 23, 2026

Vir Biotechnology, Inc.

1800 Owens Street, Suite 900

San Francisco, CA 94158

Ladies and Gentlemen:

We refer to the registration statement on Form S-8 (the "Registration Statement") to be filed by Vir Biotechnology, Inc., a Delaware corporation (the "Company"), with the Securities and Exchange Commission (the "Commission") in connection with the registration under the Securities Act of 1933, as amended (the "Act"), of an aggregate of 8,368,496 shares of the Company's Common Stock, par value $0.0001 per share (the "Shares"), that are subject to issuance by the Company (i) upon the exercise or settlement of awards to be granted under the Vir Biotechnology, Inc. 2019 Equity Incentive Plan; and (ii) upon the exercise of purchase rights to acquire Shares under the Vir Biotechnology, Inc. 2019 Employee Stock Purchase Plan. The Vir Biotechnology, Inc. 2019 Equity Incentive Plan and Vir Biotechnology, Inc. 2019 Employee Stock Purchase Plan are collectively referred to in this letter as the "Plans."

In connection with this opinion, we have reviewed the actions proposed to be taken by you in connection with the issuance and sale of the Shares to be issued under the Plans. We have also examined and relied upon the Registration Statement and the originals or copies certified to our satisfaction of such other documents, records, certificates, memoranda and other instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. With your consent, we have relied upon certificates and other assurances of officers of the Company as to factual matters without having independently verified such factual matters. We have assumed the genuineness and authenticity of all documents submitted to us as originals, and the conformity to originals of all documents submitted to us as copies thereof and the due execution and delivery of all documents where due execution and delivery are a prerequisite to the effectiveness thereof.

This opinion is being furnished in connection with the requirements of Item 601(b)(5) of Regulation S-K under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement, other than as expressly stated herein. Our opinion is limited to the matters stated herein and no opinion is implied or may be inferred beyond the matters expressly stated. Our opinion herein is expressed solely with respect to the federal laws of the United States and the General Corporation Law of the State of Delaware. Our opinion is based on these laws as in effect on the date hereof, and we disclaim any obligation to advise you of facts, circumstances, events or developments which hereafter may be brought to our attention and which may alter, affect or modify the opinion expressed herein. We are not rendering any opinion as to compliance with any federal or state antifraud law, rule or regulation relating to securities, or to the sale or issuance thereof.

Based upon and subject to the foregoing, we advise you that, in our opinion, when the Shares have been issued pursuant to the applicable provisions of the Plans and pursuant to the agreements which accompany the Plans, and in accordance with the Registration Statement, such Shares will be validly issued, fully paid and nonassessable.

------

Vir Biotechnology, Inc.

February 23, 2026

We hereby consent to the filing of this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission thereunder.

Very truly yours,

/s/ Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP

GUNDERSON DETTMER STOUGH

VILLENEUVE FRANKLIN & HACHIGIAN, LLP

## Exhibit 23.1

**Exhibit 23.1**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM** 

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the 2019 Equity Incentive Plan and the 2019 Employee Stock Purchase Plan of Vir Biotechnology, Inc. of our reports dated February 23, 2026, with respect to the consolidated financial statements of Vir Biotechnology, Inc. and the effectiveness of internal control over financial reporting of Vir Biotechnology, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2025, filed with the Securities and Exchange Commission.

/s/ Ernst & Young, LLP

San Mateo, California

February 23, 2026

<br> <br> <br>

## Ex-Filing

?xml version='1.0' encoding='ASCII'? exfilingfees

**Exhibit 107**

**Calculation of Filing Fee Tables**

**Form S-8**

(Form Type)

**Vir Biotechnology, Inc.**

(Exact Name of Registrant as Specified in its Charter)

**Table 1—Newly Registered Securities**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Security Type** | **Security Class Title** | **Fee Calculation Rule** | **Amount Registered**<sup>(1)</sup> | **Proposed Maximum Offering Price Per Share** | **Proposed Maximum Aggregate Offering Price** | **Fee Rate** | **Amount of**<br>**Registration Fee** |
| Equity | Common Stock, $0.0001 par value per share | Other | 6,973,747 shares<sup>(2)</sup> | $7.61<sup>(4)</sup> | $53070214.67<sup>(4)</sup> | $138.1<br>per<br>$1,000,000 | $7329.00 |
| Equity | Common Stock, $0.0001 par value per share | Other | 1,394,749 shares<sup>(3)</sup> | $6.47<sup>(5)</sup> | $9024026.03<sup>(5)</sup> | $138.1<br>per<br>$1,000,000 | $1246.22 |
| Total Offering Amounts | Total Offering Amounts | Total Offering Amounts | Total Offering Amounts |  | $62094240.70 |  | $8575.22 |
| Total Fee Offsets | Total Fee Offsets | Total Fee Offsets | Total Fee Offsets |  |  |  |  |
| Net Fee Due | Net Fee Due | Net Fee Due | Net Fee Due |  |  |  | $8575.22 |

---

(1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended, this Registration Statement shall also cover any additional shares of common stock that become issuable under the Vir Biotechnology, Inc. 2019 Equity Incentive Plan (the "Incentive Plan") or the Vir Biotechnology, Inc. 2019 Employee Stock Purchase Plan (the "ESPP") by reason of any stock dividend, stock split, recapitalization or any other similar transaction effected without receipt of consideration which results in an increase in the number of Vir Biotechnology, Inc.'s outstanding shares of common stock, par value $0.0001 per share (the "Common Stock").

(2) Represents additional shares of Common Stock reserved for issuance under the Incentive Plan as a result of the automatic increase in shares reserved thereunder on January 1, 2026, pursuant to the terms of the Incentive Plan. The Incentive Plan provides that an additional number of shares will automatically be added annually to the shares authorized for issuance under the Incentive Plan on January 1, 2020 and ending on (and including) January 1, 2029, in an amount equal to the lesser of (a) 5% of the total number of shares of Vir Biotechnology, Inc.'s capital stock outstanding on December 31 of the preceding calendar year and (b) a number of shares of Common Stock designated by action of Vir Biotechnology, Inc.'s board of directors prior to the first day of any calendar year.

(3) Represents additional shares of Common Stock reserved for issuance under the ESPP as a result of the automatic increase in shares reserved thereunder on January 1, 2026, pursuant to the terms of the ESPP. The ESPP provides that an additional number of shares will automatically be added annually to the shares authorized for issuance under the ESPP on January 1, 2020 and ending on (and including) January 1, 2029, in an amount equal to the lesser of: (a) 1% of the total number of shares of Vir Biotechnology, Inc.'s capital stock outstanding on December 31 of the preceding calendar year; (b) 2,700,000 shares of Common Stock and (c) a number of shares of Common Stock designated by action of Vir Biotechnology, Inc.'s board of directors prior to the first day of any calendar year.

(4) Estimated pursuant to Rule 457(c) and Rule 457(h) solely for the purpose of calculating the registration fee. The proposed maximum offering price per share and proposed maximum aggregate offering price are based on the average of the high and low sale prices of Vir Biotechnology, Inc.'s common stock as reported on The Nasdaq Global Select Market on February 17, 2026, which date is within five business days prior to the filing of the Registration Statement.

(5) Estimated pursuant to Rule 457(c) and Rule 457(h) solely for the purpose of calculating the registration fee. The proposed maximum offering price per share and proposed maximum aggregate offering price are based on the average of the high and low sales prices of Vir Biotechnology, Inc.'s common stock as reported on The Nasdaq Global Select Market on February 17, 2026, multiplied by 85%, which date is within five business days prior to the filing of the Registration Statement, multiplied by 85%, which is the percentage of the price per share applicable to purchasers under the ESPP.